Drug Trial Radar · NCT07128888
Study on Gastric Emptying Effect and Drug-Drug Interactions of GZR18 Injection
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Sep 24, 2025
Primary completion
Apr 13, 2026
Study completion Apr 13, 2026
Sponsor
- Lead sponsor
- Gan & Lee Pharmaceuticals.Industry
- Sponsor type
- Industry
- First posted
- Aug 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, fixed-sequence phase I clinical study to evaluate the effect of GZR18 Injection on gastric emptying and the effect of repeated SC injections of GZR18 Injection on the pharmacokinetics of oral digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tablets. A total of 60 obese or overweight subjects are planned to be enrolled, with no less than one-quarter of the subjects from either gender. The study duration for each subject in this study is approximately 26 weeks: including a screening period of up to 4 weeks (W-28 to D-1), single-drug administration and dose escalation stages of 16 weeks (W1D1 to W16D7) and the combined drug administration stage of 6 weeks (W17D1 to W23D1)
Conditions
- Obesity or Overweight
Interventions
GZR18 injection,digoxin tablets, rosuvastatin calcium tablets and warfarin sodium tabletsDrug
GZR18 injection: 3 mg-36 mg,16 weeks; Warfarin Sodium Tablets:2.5mg,twice; Rosuvastatin Calcium Tablets:10mg,twice; Digoxin Tablets:0.25mg,twice
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax:Maximum plasma concentrationTime frame: through study completion,up to 16 weeks
- AUC0-last:Area under the plasma concentration-time curve at 0 h to last observation time-point after a single dose.Time frame: through study completion,up to 16 weeks
- AUC0-inf:Area under the plasma concentration-time curve at 0 h to infinity after a single dose.Time frame: through study completion,up to 16 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Study site 01
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.